Glenmark’s US arm launches Vancomycin Hydrochloride for injection USP

01 Apr 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has launched Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark’s Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories, NDA 209481.

According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of around $39.3 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 

Glenmark Pharma Share Price

1390.10 21.10 (1.54%)
22-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.25
Dr. Reddys Lab 1174.85
Cipla 1528.10
Lupin 2046.90
Zydus Lifesciences 852.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...